Your browser doesn't support javascript.
loading
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.
Li, Zheqi; McGinn, Olivia; Wu, Yang; Bahreini, Amir; Priedigkeit, Nolan M; Ding, Kai; Onkar, Sayali; Lampenfeld, Caleb; Sartorius, Carol A; Miller, Lori; Rosenzweig, Margaret; Cohen, Ofir; Wagle, Nikhil; Richer, Jennifer K; Muller, William J; Buluwela, Laki; Ali, Simak; Bruno, Tullia C; Vignali, Dario A A; Fang, Yusi; Zhu, Li; Tseng, George C; Gertz, Jason; Atkinson, Jennifer M; Lee, Adrian V; Oesterreich, Steffi.
Afiliación
  • Li Z; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
  • McGinn O; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Wu Y; Magee-Womens Research Institute, Pittsburgh, PA, USA.
  • Bahreini A; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Priedigkeit NM; Magee-Womens Research Institute, Pittsburgh, PA, USA.
  • Ding K; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Onkar S; Magee-Womens Research Institute, Pittsburgh, PA, USA.
  • Lampenfeld C; School of Medicine, Tsinghua University, Beijing, China.
  • Sartorius CA; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Miller L; Magee-Womens Research Institute, Pittsburgh, PA, USA.
  • Rosenzweig M; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA.
  • Cohen O; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Wagle N; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Richer JK; Magee-Womens Research Institute, Pittsburgh, PA, USA.
  • Muller WJ; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Buluwela L; Magee-Womens Research Institute, Pittsburgh, PA, USA.
  • Ali S; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Bruno TC; Magee-Womens Research Institute, Pittsburgh, PA, USA.
  • Vignali DAA; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Fang Y; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Zhu L; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Tseng GC; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Gertz J; Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Atkinson JM; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Lee AV; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Oesterreich S; Womens Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Nat Commun ; 13(1): 2011, 2022 04 19.
Article en En | MEDLINE | ID: mdl-35440136
ABSTRACT
Estrogen receptor alpha (ER/ESR1) is frequently mutated in endocrine resistant ER-positive (ER+) breast cancer and linked to ligand-independent growth and metastasis. Despite the distinct clinical features of ESR1 mutations, their role in intrinsic subtype switching remains largely unknown. Here we find that ESR1 mutant cells and clinical samples show a significant enrichment of basal subtype markers, and six basal cytokeratins (BCKs) are the most enriched genes. Induction of BCKs is independent of ER binding and instead associated with chromatin reprogramming centered around a progesterone receptor-orchestrated insulated neighborhood. BCK-high ER+ primary breast tumors exhibit a number of enriched immune pathways, shared with ESR1 mutant tumors. S100A8 and S100A9 are among the most induced immune mediators and involve in tumor-stroma paracrine crosstalk inferred by single-cell RNA-seq from metastatic tumors. Collectively, these observations demonstrate that ESR1 mutant tumors gain basal features associated with increased immune activation, encouraging additional studies of immune therapeutic vulnerabilities.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor alfa de Estrógeno Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor alfa de Estrógeno Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos